Phase 2 titration schedule, mechanism, and clinical trial weight loss data for the triple GLP-1/GIP/glucagon agonist
Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly. It is the first compound in the GLP-1 class to add glucagon receptor agonism, which increases energy expenditure through thermogenesis and hepatic fat oxidation — producing the highest weight loss of any GLP-1 agent in clinical trials. Phase 2 data showed ~24% mean body weight reduction at 48 weeks with 12 mg/week.
Source: Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM 2023. N=338 participants with obesity (BMI ≥30), 48-week treatment period.
| Period | Dose | Phase | Notes |
|---|---|---|---|
| Weeks 1–4 | 2 mg/week | Initiation | Lowest dose to establish tolerability. GI side effects most likely during this phase. |
| Weeks 5–8 | 4 mg/week | Escalation 1 | First dose increase. Monitor for nausea and vomiting. Maintain dose if side effects are significant. |
| Weeks 9–12 | 8 mg/week | Escalation 2 | Significant weight loss typically begins. GI effects usually diminishing by this phase. |
| Weeks 13+ | 12 mg/week | Maintenance | Maximum dose used in Phase 2 trials. ~24% mean weight loss at 48 weeks at this dose. |
The key differentiator is glucagon receptor agonism. GLP-1 and GIP agonism primarily reduce caloric intake through appetite suppression and satiety signaling. Glucagon agonism adds a second mechanism: increased energy expenditure. Glucagon stimulates thermogenesis in brown adipose tissue and increases hepatic fatty acid oxidation — meaning retatrutide both reduces calories consumed and increases calories burned.
This dual-mechanism approach (reduced intake + increased expenditure) is why retatrutide's weight loss exceeds that of tirzepatide (dual GLP-1/GIP) and semaglutide (GLP-1 only) in Phase 2 data, despite a shorter trial duration (48 weeks vs 68–72 weeks for the others).
| Compound | Weight Loss | Duration | Mechanism |
|---|---|---|---|
| Semaglutide 2.4mg | ~15% | 68 weeks | GLP-1 |
| Tirzepatide 15mg | ~22% | 72 weeks | GLP-1 + GIP |
| Retatrutide 12mg | ~24% | 48 weeks | GLP-1 + GIP + Glucagon |
In Phase 2 trials, 42% of participants in the 12 mg/week group reported nausea. GI side effects were the primary reason for dose reduction or discontinuation. Strict adherence to the titration schedule is critical for tolerability.
If GI side effects are significant at any dose level, maintaining the current dose for an additional 4 weeks before escalating is preferable to discontinuation. The GI effects of retatrutide, like other GLP-1 agents, typically diminish over 4–8 weeks as the body adapts to the compound.
Phase 2 clinical trials showed a mean body weight reduction of approximately 24% at 48 weeks with the highest dose (12 mg/week). The 8 mg/week group achieved ~22% weight loss. These are the highest weight loss figures reported for any GLP-1 class agent in clinical trials.
The Phase 2 trial used a gradual titration: 2 mg/week for 4 weeks, then 4 mg/week for 4 weeks, then 8 mg/week for 4 weeks, then 12 mg/week maintenance. This slow escalation minimizes GI side effects, which are the primary dose-limiting factor.
Retatrutide produced ~24% weight loss at 48 weeks vs ~15% for semaglutide at 68 weeks. However, these are from separate trials with different populations and durations. Retatrutide's glucagon receptor agonism — which increases energy expenditure — is the key mechanistic difference driving its superior weight loss.
As of 2025, retatrutide is in Phase 3 clinical trials and is not yet FDA-approved. Research-grade retatrutide is available for laboratory research purposes only.
The most common side effects in Phase 2 trials were nausea (42% at highest dose), vomiting, and diarrhea — consistent with the GLP-1 class. These were most pronounced during dose escalation and generally decreased over time. Gradual titration is essential for tolerability.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.